These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

604 related items for PubMed ID: 27221037

  • 1. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer.
    Zhao J, Zhao Y, Wang L, Zhang J, Karnes RJ, Kohli M, Wang G, Huang H.
    Oncotarget; 2016 Jun 21; 7(25):38551-38565. PubMed ID: 27221037
    [Abstract] [Full Text] [Related]

  • 2. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Abudurexiti M, Zhu W, Wang Y, Wang J, Xu W, Huang Y, Zhu Y, Shi G, Zhang H, Zhu Y, Shen Y, Dai B, Wan F, Lin G, Ye D.
    Prostate; 2020 Sep 21; 80(12):950-961. PubMed ID: 32648618
    [Abstract] [Full Text] [Related]

  • 3. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant ARF876L nuclear import and function.
    Wu Z, Wang K, Yang Z, Pascal LE, Nelson JB, Takubo K, Wipf P, Wang Z.
    Prostate; 2020 Mar 21; 80(4):319-328. PubMed ID: 31868960
    [Abstract] [Full Text] [Related]

  • 4. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC.
    Clin Cancer Res; 2014 Jun 15; 20(12):3198-3210. PubMed ID: 24740322
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Bai Y, Zhang Z, Cheng L, Wang R, Chen X, Kong Y, Feng F, Ahmad N, Li L, Liu X.
    J Biol Chem; 2019 Jun 21; 294(25):9911-9923. PubMed ID: 31085587
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Wu H, Zhang L, Gao X, Zhang X, Duan J, You L, Cheng Y, Bian J, Zhu Q, Yang Y.
    Cancer Lett; 2017 Jan 28; 385():108-116. PubMed ID: 27815035
    [Abstract] [Full Text] [Related]

  • 8. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
    Fernandez EV, Reece KM, Ley AM, Troutman SM, Sissung TM, Price DK, Chau CH, Figg WD.
    Mol Pharmacol; 2015 Jun 28; 87(6):1006-12. PubMed ID: 25829060
    [Abstract] [Full Text] [Related]

  • 9. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
    Kregel S, Chen JL, Tom W, Krishnan V, Kach J, Brechka H, Fessenden TB, Isikbay M, Paner GP, Szmulewitz RZ, Vander Griend DJ.
    Oncotarget; 2016 May 03; 7(18):26259-74. PubMed ID: 27036029
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ, de Morrée ES, Kweldam CF, de Ridder CMA, Wiemer EAC, Mathijssen RHJ, de Wit R, van Weerden WM.
    Eur Urol; 2015 Jun 03; 67(6):981-985. PubMed ID: 25484141
    [Abstract] [Full Text] [Related]

  • 12. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
    Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, Heiser LM, Alumkal JJ.
    Oncotarget; 2016 Jun 28; 7(26):40690-40703. PubMed ID: 27276681
    [Abstract] [Full Text] [Related]

  • 13. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
    Pal SK, Patel J, He M, Foulk B, Kraft K, Smirnov DA, Twardowski P, Kortylewski M, Bhargava V, Jones JO.
    Cancer; 2018 Mar 15; 124(6):1216-1224. PubMed ID: 29266182
    [Abstract] [Full Text] [Related]

  • 14. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ, Chou FJ, Li L, Lin CY, Yeh S, Chang C.
    Cancer Lett; 2017 Jul 10; 398():62-69. PubMed ID: 28373004
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Chen X, Liu J, Cheng L, Li C, Zhang Z, Bai Y, Wang R, Han T, Huang C, Kong Y, Feng F, Liu X.
    Prostate; 2020 Feb 10; 80(3):256-266. PubMed ID: 31856338
    [Abstract] [Full Text] [Related]

  • 16. Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.
    Russo JW, Gao C, Bhasin SS, Voznesensky OS, Calagua C, Arai S, Nelson PS, Montgomery B, Mostaghel EA, Corey E, Taplin ME, Ye H, Bhasin M, Balk SP.
    Cancer Res; 2018 Nov 15; 78(22):6354-6362. PubMed ID: 30242112
    [Abstract] [Full Text] [Related]

  • 17. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
    Schalken J, Fitzpatrick JM.
    BJU Int; 2016 Feb 15; 117(2):215-25. PubMed ID: 25818596
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R, Lin W, Lin C, Li L, Sun Y, Chang C.
    Cancer Lett; 2016 Aug 28; 379(1):154-60. PubMed ID: 27233475
    [Abstract] [Full Text] [Related]

  • 20. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M, Huang Y, Ratnam M.
    Biochem Biophys Res Commun; 2016 Jul 22; 476(2):69-74. PubMed ID: 27179779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.